Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro
29/09/2026 11:28
Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro COPENHAGEN, Sept 29 (Reuters) - Novo Nordisk NOVOb.CO said on Tuesday a real-world study found that adults with type 2 diabetes who escalated their dose of diabetes drug Ozempic to 2 milligrams (mg) from 1 mg had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's Mounjaro.
(Reporting by Louise Rasmussen, editing by Stine Jacobsen)
((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))
Recent news on Novo Nordisk A/S
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
India's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption